Inherited Abnormalities of Coagulation. Hemophilia, von Willebrand Disease, and Beyond.

Pediatric Clinics of North America

Volumn 60, Issue 6, 2013, Pages 1419-1441

  Kumar, Riten ^a   Carcao, Manuel ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

Hemophilia; Hemostasis; Rare factor deficiency; Von Willebrand disease

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DESMOPRESSIN; ENZYME PRECURSOR; TRANEXAMIC ACID; VACCINE; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CONTINUOUS INFUSION; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MOLECULAR PATHOLOGY; MUSCLE BLEEDING; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROPHYLAXIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOPLASTIN TIME; VASOCONSTRICTION; VON WILLEBRAND DISEASE;

HEMOPHILIA; HEMOSTASIS; RARE FACTOR DEFICIENCY; VON WILLEBRAND DISEASE;

BLOOD COAGULATION; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; VON WILLEBRAND DISEASES;

EID: 84887528087     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2013.09.002     Document Type: Review

References (102)

1. Israels S.J., Kahr W.H., Blanchette V.S., et al. Platelet disorders in children: a diagnostic approach. Pediatr Blood Cancer 2011, 56(6):975-983.
2. Israels S.J., Rand M.L. What we have learned from inherited platelet disorders. Pediatr Blood Cancer 2013, 60(Suppl 1):S2-S7.
3. Revel-Vilk S.R., Rand M.L., Israles S.J. Primary and secondary hemostasis, regulators of coagulation, and fibrinolysis: understanding the basics. SickKids handbook of pediatric thrombosis and hemostasis 2013, Karger, Basel (Switzerland). 1st edition.
4. Lippi G., Franchini M., Montagnana M., et al. Inherited disorders of blood coagulation. An Med 2012, 44(5):405-418.
5. Lippi G., Favaloro E.J., Franchini M., et al. Milestones and perspectives in coagulation and hemostasis. Semin Thromb Hemost 2009, 35(1):9-22.
6. Goodnight S.H., Hathaway W.E. Mechanisms of Hemostasis and Thrombosis. Disorders of Haemostasis and Thrombosis 2001, McGraw-Hill, Lancester (PA). 2nd edition.
7. Kamal A.H., Tefferi A., Pruthi R.K. How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 2007, 82(7):864-873.
8. Mann K.G. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999, 82(2):165-174.
9. Stonebraker J.S., Bolton-Maggs P.H., Michael Soucie J., et al. Astudy of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012, 18(3):e91-e94.
10. Stonebraker J.S., Bolton-Maggs P.H., Soucie J.M., et al. Astudy of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010, 16(1):20-32.
11. Soucie J.M., Evatt B., Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998, 59(4):288-294.
12. White G.C., Rosendaal F., Aledort L.M., et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001, 85(3):560.
13. Bowen D.J. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002, 55(2):127-144.
14. Gitschier J., Wood W.I., Goralka T.M., et al. Characterization of the human factor VIII gene. Nature 1984, 312(5992):326-330.
15. Yoshitake S., Schach B.G., Foster D.C., et al. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry 1985, 24(14):3736-3750.
16. Carcao M.D. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012, 38(7):727-734.
17. Graw J., Brackmann H.H., Oldenburg J., et al. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005, 6(6):488-501.
18. Lillicrap D. The molecular basis of haemophilia B. Haemophilia 1998, 4(4):350-357.
19. Antonarakis S.E., Rossiter J.P., Young M., et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995, 86(6):2206-2212.
20. Rossiter J.P., Young M., Kimberland M.L., et al. Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells. Hum Mol Genet 1994, 3(7):1035-1039.
21. Picketts D.J., Mueller C.R., Lillicrap D. Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations. Blood 1994, 84(9):2992-3000.
22. Carcao M.D., van den Berg H.M., Ljung R., et al. Correlation between phenotype and genotype in a large unselected cohort of children with severe hemophilia A. Blood 2013, 121(19):3946-3952.
23. Mannucci P.M., Franchini M. Is haemophilia B less severe than haemophilia A?. Haemophilia 2013, 19(4):499-502.
24. Kulkarni R., Soucie J.M. Pediatric hemophilia: a review. Semin Thromb Hemost 2011, 37(7):737-744.
25. Kulkarni R., Soucie J.M., Lusher J., et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009, 15(6):1281-1290.
26. Richards M., Lavigne Lissalde G., Combescure C., et al. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012, 156(3):374-382.
27. Kulkarni R., Lusher J.M. Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. JPediatr Hematol Oncol 1999, 21(4):289-295.
28. James A.H., Hoots K. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery. Haemophilia 2010, 16(3):420-424.
29. Ljung R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery. Haemophilia 2010, 16(3):415-419.
30. Chalmers E., Williams M., Brennand J., et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011, 154(2):208-215.
31. Witmer C., Presley R., Kulkarni R., et al. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011, 152(2):211-216.
32. van Dijk K., Fischer K., van der Bom J.G., et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005, 11(5):438-443.
33. Franchini M., Montagnana M., Targher G., et al. Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. Semin Thromb Hemost 2009, 35(3):307-312.
34. van Dijk K., van der Bom J.G., Fischer K., et al. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004, 92(2):305-310.
35. Valentino L.A. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. JThromb Haemost 2010, 8(9):1895-1902.
36. Sorensen B., Benson G.M., Bladen M., et al. Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world. Haemophilia 2012, 18(4):598-606.
37. Kumar R., Pruthi R.K., Kobrinsky N., et al. Pelvic pseudotumor and pseudoaneurysm in a pediatric patient with moderate hemophilia B: successful management with arterial embolization and surgical excision. Pediatr Blood Cancer 2011, 56(3):484-487.
38. Berntorp E., Halimeh S., Gringeri A., et al. Management of bleeding disorders in children. Haemophilia 2012, 18(Suppl 2):15-23.
39. de Moerloose P., Fischer K., Lambert T., et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012, 18(3):319-325.
40. Barnes C. Importance of pharmacokinetics in the management of hemophilia. Pediatr Blood Cancer 2013, 60(Suppl 1):S27-S29.
41. Collins P.W., Bjorkman S., Fischer K., et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. JThromb Haemost 2010, 8(2):269-275.
42. Batorova A., Holme P., Gringeri A., et al. Continuous infusion in haemophilia: current practice in Europe. Haemophilia 2012, 18(5):753-759.
43. Batorova A., Martinowitz U. Continuous infusion of coagulation factors: current opinion. Curr Opin Hematol 2006, 13(5):308-315.
44. Srivastava A., Brewer A.K., Mauser-Bunschoten E.P., et al. Guidelines for the management of hemophilia. Haemophilia 2013, 19(1):e1-47.
45. Robertson JD, Curtin JA, Blanchette VS. Managing Hemophilia in Children and Adolescents. Sick Kids Handbook of pediatric thrombosis and hemostasis. 1st edition. Basel (Switzerland) Karger; 2013.
46. Mannucci P.M., Ghirardini A. Desmopressin: twenty years after. Thromb Haemost 1997, 78(2):958.
47. Seary M.E., Feldman D., Carcao M.D. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII: C level and with haemophilic genotype. Haemophilia 2012, 18(1):50-55.
48. Nilsson I.M., Hedner U., Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976, 65(2):129-135.
49. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965, (Suppl 77):73-132.
50. Nilsson I.M., Berntorp E., Lofqvist T., et al. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. JIntern Med 1992, 232(1):25-32.
51. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. NEngl J Med 2007, 357(6):535-544.
52. Valentino L.A., Kawji M., Grygotis M. Venous access in the management of hemophilia. Blood Rev 2011, 25(1):11-15.
53. Feldman B.M., Pai M., Rivard G.E., et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. JThromb Haemost 2006, 4(6):1228-1236.
54. Fogarty P.F. Biological rationale for new drugs in the bleeding disorders pipeline. Hematology Am Soc Hematol Educ Program 2011, 2011:397-404.
55. Nathwani A.C., Tuddenham E.G., Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. NEngl J Med 2011, 365(25):2357-2365.
56. Santagostino E., Morfini M., Auerswald G.K., et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia 2009, 15(5):983-989.
57. Gouw S.C., van den Berg H.M., Oldenburg J., et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012, 119(12):2922-2934.
58. Pavlova A., Delev D., Lacroix-Desmazes S., et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. JThromb Haemost 2009, 7(12):2006-2015.
59. Gouw S.C., van der Bom J.G., Auerswald G., et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007, 109(11):4693-4697.
60. Gouw S.C., van der Bom J.G., Ljung R., et al. Factor VIII products and inhibitor development in severe hemophilia A. NEngl J Med 2013, 368(3):231-239.
61. Iorio A., Halimeh S., Holzhauer S., et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. JThromb Haemost 2010, 8(6):1256-1265.
62. Astermark J., Donfield S.M., DiMichele D.M., et al. Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109(2):546-551.
63. Hay C.R., DiMichele D.M. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012, 119(6):1335-1344.
64. Berntorp E., Shapiro A., Astermark J., et al. Inhibitor treatment in haemophilias A and B: summary statement for the 2006 international consensus conference. Haemophilia 2006, 12(Suppl 6):1-7.
65. Hay C.R., Brown S., Collins P.W., et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006, 133(6):591-605.
66. Rodeghiero F., Castaman G., Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987, 69(2):454-459.
67. Werner E.J., Broxson E.H., Tucker E.L., et al. Prevalence of von Willebrand disease in children: a multiethnic study. JPediatr 1993, 123(6):893-898.
68. Bowman M., Hopman W.M., Rapson D., et al. The prevalence of symptomatic von Willebrand disease in primary care practice. JThromb Haemost 2010, 8(1):213-216.
69. James P.D., Lillicrap D. The molecular characterization of von Willebrand disease: good in parts. Br J Haematol 2013, 161(2):166-176.
70. Robertson J., Lillicrap D., James P.D. Von Willebrand disease. Pediatr Clin North Am 2008, 55(2):377-392. viii-ix.
71. Mancuso D.J., Tuley E.A., Westfield L.A., et al. Structure of the gene for human von Willebrand factor. JBiol Chem 1989, 264(33):19514-19527.
72. Fowler W.E., Fretto L.J., Hamilton K.K., et al. Substructure of human von Willebrand factor. JClin Invest 1985, 76(4):1491-1500.
73. Dong J.F., Moake J.L., Nolasco L., et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002, 100(12):4033-4039.
74. Cumming A., Grundy P., Keeney S., et al. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006, 96(5):630-641.
75. Goodeve A., Eikenboom J., Castaman G., et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007, 109(1):112-121.
76. James P.D., Notley C., Hegadorn C., et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007, 109(1):145-154.
77. Sadler J.E., Budde U., Eikenboom J.C., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. JThromb Haemost 2006, 4(10):2103-2114.
78. Carcao M.D., Blanchette V.S., Dean J.A., et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998, 101(1):70-73.
79. Dean J.A., Blanchette V.S., Carcao M.D., et al. von Willebrand disease in a pediatric-based population-comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay. Thromb Haemost 2000, 84(3):401-409.
80. Conlan M.G., Folsom A.R., Finch A., et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993, 70(3):380-385.
81. Jenkins P.V., O'Donnell J.S. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 2006, 46(10):1836-1844.
82. Nichols W.L., Hultin M.B., James A.H., et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008, 14(2):171-232.
83. Gupta M., Lillicrap D., Stain A.M., et al. Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease. Pediatr Blood Cancer 2011, 57(6):1081-1083.
84. Ross C.S., Pruthi R.K., Schmidt K.A., et al. Intranasal oestrogen cream for the prevention of epistaxis in patients with bleeding disorders. Haemophilia 2011, 17(1):164.
85. Ben-Ami T., Revel-Vilk S. The use of DDAVP in children with bleeding disorders. Pediatr Blood Cancer 2013, 60(Suppl 1):S41-S43.
86. Abshire T.C., Federici A.B., Alvarez M.T., et al. Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN). Haemophilia 2013, 19(1):76-81.
87. Rodeghiero F., Castaman G., Tosetto A. How I treat von Willebrand disease. Blood 2009, 114(6):1158-1165.
88. Bolton-Maggs P.H. The rare inherited coagulation disorders. Pediatr Blood Cancer 2013, 60(Suppl 1):S37-S40.
89. Mannucci P.M., Duga S., Peyvandi F. Recessively inherited coagulation disorders. Blood 2004, 104(5):1243-1252.
90. Peyvandi F., Bolton-Maggs P.H., Batorova A., et al. Rare bleeding disorders. Haemophilia 2012, 18(Suppl 4):148-153.
91. Gomez K., Bolton-Maggs P. Factor XI deficiency. Haemophilia 2008, 14(6):1183-1189.
92. Lapecorella M., Mariani G. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options. Haemophilia 2008, 14(6):1170-1175.
93. Peyvandi F., Spreafico M. National and international registries of rare bleeding disorders. Blood Transfus 2008, 6(Suppl 2):s45-s48.
94. Peyvandi F., Di Michele D., Bolton-Maggs P.H., et al. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. JThromb Haemost 2012, 10(9):1938-1943.
95. Kohler H.P., Ichinose A., Seitz R., et al. Diagnosis and classification of factor XIII deficiencies. JThromb Haemost 2011, 9(7):1404-1406.
96. Acharya S.S., Dimichele D.M. Rare inherited disorders of fibrinogen. Haemophilia 2008, 14(6):1151-1158.
97. Hsieh L., Nugent D. Factor XIII deficiency. Haemophilia 2008, 14(6):1190-1200.
98. Inbal A., Oldenburg J., Carcao M., et al. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012, 119(22):5111-5117.
99. Brown D.L., Kouides P.A. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008, 14(6):1176-1182.
100. Huang J.N., Koerper M.A. Factor V deficiency: a concise review. Haemophilia 2008, 14(6):1164-1169.
101. Meeks S.L., Abshire T.C. Abnormalities of prothrombin: a review of the pathophysiology, diagnosis, and treatment. Haemophilia 2008, 14(6):1159-1163.
102. Bolton-Maggs P.H., Perry D.J., Chalmers E.A., et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004, 10(5):593-628.